. Introduction
impaired. Carnitine plays an important role in the transport of long-chain fatty acids into the mitochondrial matrix for Disorders of cardiac energy metabolism, which include b-oxidation [4] . Thus, disorder of mitochondrial b-oxidadefects in fatty acid oxidation, induce cardiac hypertrophy tion is present in the JVS mouse and leads to the [1] . However, the mechanisms of cardiomyopathy in these development of marked cardiac hypertrophy [5] . In addidisorders are not yet entirely understood. Recently, the tion, carnitine treatment has also been shown to inhibit juvenile visceral steatosis (JVS) mouse, a genetic model of cardiac hypertrophy in JVS mice. systemic carnitine deficiency, was established [2] . The JVS Etomoxir, a hypoglycemic agent with no acute sidemouse results from mutations of the renal carnitine transeffects, is an oxirane carboxylic acid derivative that porter gene [3] , and renal conservation of carnitine is specifically inactivates carnitine palmitoyltransferase I (CPT-I), the key enzyme for the transport of long-chain acyl-CoA compounds into mitochondria. Etomoxir pro-motes cardiac growth and increases myosin isoenzyme V JVS mice with inhibited cardiac hypertrophy; 1% carnitine 1 [6] . Cardiac growth induced by etomoxir in non-over-(10 mg / kg) was administered from 4 to 8 weeks of age. loaded ventricles is associated with concentric hypertrophy
(1)-Etomoxir sodium salt (45 mg / kg / d) was administered [7] . The mechanisms underlying this etomoxir-induced to normal mice in their drinking water for 4 weeks, from 4 hypertrophic growth with a unique myocardial phenotype to 8 weeks of age. The dose was maintained by monitoring are unknown, but they are assumed to be related to CPT-1 the animals' daily water consumption and body weight. inhibition. Since both the JVS mouse and etomoxir-treated
Wild-type animals of the C3H strain were used as the mice show a disorder of fatty acid b-oxidation and lipid control. accumulation in myocardial tissue, the evaluation of lipid second messengers seems to be of importance to elucidate 2 .2. Blood pressure and echocardiographic the pathogenesis of cardiac hypertrophy in these models. measurements The generation of second messengers from precursor molecules is one of the earliest changes in cells stimulated
On the day of sacrifice, the systolic blood pressure and by hormones and growth factors. 1,2-DAG is one such heart rate were determined for each animal. The tail-cuff second messenger and is an endogenous activator of method was used, employing a photoelectric tail-cuff protein kinase C (PKC) [8] . PKC regulates many biodetection system (Softron BP-98A; Softron, Tokyo, Japan). logical processes, such as differentiation and mitosis.
Left ventricular (LV) contractile function was evaluated by Ceramide is a product of sphingomyelin breakdown by transthoracic echocardiography using a EUB 8000 CV sphingomyelinase and also acts as a lipid second mes-(Hitachi, Tokyo, Japan) with a 10-MHz imaging transsenger to mediate the effects of extracellular agents on ducer. In brief, each animal was slightly sedated with 21 differentiation, growth inhibition, and apoptosis [9] . Given sodium pentobarbital (20 mg kg i.p.). M-mode images of that sphingolipid metabolites, including ceramide, have the LV at the level of the chordae tendineae were recorded, been demonstrated to inhibit PKC activity, ceramide may and LV dimensions at end-diastole (EDD) and end-systole counter 1,2-DAG-mediated action [10] .
(ESD) were measured by means of the leading edge In the present study, we investigated the difference method. For each measurement, data from three cardiac between two disorder models of b-oxidation, the heredity cycles were averaged, and fractional shortening was calcuand pharmacological interventional models, and carnitinelated as treated JVS mice, the model of inhibited cardiac hy-%FS 5 (EDD 2 ESD) / EDD 3 100 pertrophy. It is important to investigate the changes in 1,2-DAG and ceramide mass in experimental models in 2 .3. Tissue sampling which PKC may be involved. In this study, we measured myocardial lipid levels, including 1,2-DAG and ceramide, Each animal was anesthetized with diethyl ether. The by means of Iatroscan thin-layer chromatography with hearts were rapidly excised and washed thoroughly with flame ionization detection (TLC / FID) [11] , and investicold saline, then immediately frozen in liquid nitrogen and gated the involvement of these lipid messengers in cardiac lyophilized. hypertrophy in these models.
.4. Lipid analysis

. Methods
The lyophilized heart samples were homogenized in 5 2 .1. Animal preparation ml of a chilled chloroform / methanol mixture (2:1, by vol) containing 0.01% butylated hydroxytoluene as an antiThe investigation conformed to the Guide for the Care oxidant and cholesteryl acetate as an internal standard. The and Use of Laboratory Animals published by the US phospholipid content was quantified using the TLC / FID National Institute of Health (NIH Publication No. 85-23, method as previously described [11] . Simultaneous quantirevised 1996). The JVS mice were of the C3H strain [3], tation of 1,2-DAG and ceramide levels was also performed and were kindly donated by Dr. Nikaido, Institute for by the TLC / FID method as previously described [13] . In Experimental Animals, Kanazawa University School of brief, 1 ml of a lipid extract solution containing ceramides, Medicine, Kanazawa, Japan. All animals were maintained neutral lipids, and free fatty acids was dissolved in under specific pathogen-free conditions. chloroform and applied carefully to silica gel using 75 mm Homozygous mutants (jvs / jvs) had swollen fatty livers precoated thin-layer rods (Chromarod-SIII, Iatron Lab., that were recognizable through the abdominal wall 5 days Tokyo, Japan). The first development was carried out in a after birth. We treated the homozygous mutants with 5 solvent system of chloroform / methanol / H O (57:12:0.6, 2 mmol of L-carnitine from 11 to 20 days after birth in order by vol) until the solvent front had migrated approximately to prolong their lives according to a previously reported 2.5 cm. The second development was carried out in 1,2-method [12] . In addition, we produced carnitine-treated dichloroethane / chloroform / acetic acid (46:6:0.05, by vol) until the solvent had migrated approximately 9 cm. The comparisons were assessed by one-way ANOVA and third development consisted of a repetition of the second Scheffe's test. For the fatty acid composition of 1,2-DAG, development. The fourth development was carried out in the Mann-Whitney U-test was used. P,0.05 was considn-hexane / diethyl ether / acetic acid (98:1:1, by vol) until ered statistically significant. the solvent front had migrated approximately 11.5 cm. The Chromarods were then scanned in an Iatroscan MK-5 analyzer (Iatron Lab.). Each sample was analyzed with three Chromarods, and the results were averaged.
. Results
The heart weight in the JVS group was elevated from 4 2 .5. Measurement of the fatty acid composition of 1,2-weeks of age and comparable to that of the control group. DAG At 8 weeks of age, the heart weight in both the JVS and the etomoxir-treated control group was significantly inFollowing the quantification of 1,2-DAG and ceramide, creased compared with that in the control group. The heart the remaining lipids were separated using silica gel plates weight in the carnitine-treated JVS group was significantly (20320 cm, Kieselgel 60 F254, Merck, Darmstadt, Gerdecreased compared with that in the JVS group. However, many). The area corresponding to 1,2-DAG was identified no difference was observed in body weight among the by exposure of 1,2-diolein to iodine vapor, and scraped groups. The heart weight / body weight ratios in both the into a 2 ml chloroform / methanol mixture (9:1, v / v). The etomoxir-treated and JVS groups were much higher than extract was evaporated to dryness under a stream of N 2 that in the control group at 8 weeks of age, but that in the gas, and the fatty acyl moieties in this fraction were carnitine-treated JVS group was significantly decreased transmethylated with boron fluoride-methanol [14] .
compared with that in JVS group (Table 1) . Methyl fatty acids were analyzed on a gas chromatograph (Model GC 14-A, Shimadzu, Kyoto, Japan) equipped with a flame ionization detector and an HR-SS-10 fused-silica 3 .1. Myocardial performance capillary column (30 m30.25 mm internal diameter, Shinwakakoh, Kyoto, Japan). Peaks were identified by
In the JVS and carnitine-treated JVS groups, systolic comparison to standards (Nu-Chek-Prep, Elysian, MN, blood pressure and fractional shortening of the left ventri-USA), and the peak areas were calculated.
cle as measured by echocardiography were significantly decreased compared with those in the control group. However, in the carnitine-treated JVS group, systolic blood 2 .6. Morphological study pressure was elevated and fractional shortening of the left ventricle was slightly, but not significantly, improved Cardiac tissue was examined by means of light microcompared with these factors in the JVS group. Furtherscopy. Tissue was fixed in 10% formaldehyde in phosphate more, these parameters showed a tendency to decrease to buffer, and paraffin sections at a thickness of 4 mm were the values in the etomoxir-treated group (Table 2) . examined after staining with hematoxylin-eosin.
.7. Statistics 3 .2. Histological analysis
Results are expressed as mean6S.E. Between-group In transverse sections, the walls of the left and right Table 1 Heart weight, body weight and heart weight / body weight ratio for the JVS, etomoxir-treated control, carnitine-treated JVS and control groups ventricles in both the JVS and etomoxir-treated groups were increased in thickness compared to those in the control group. No apparent difference in pathologic histology was seen between the control and carnitine-treated those in the JVS group. However, myocardial sphing-JVS groups (Fig. 1) . Myocardial fibrosis in the JVS and omyelin contents were significantly decreased in the JVS etomoxir-treated groups was not obviously present in group compared with those in the control group. No comparison with the control group based on a comparison differences in other lipid contents were observed among of myocardial tissues after examination by means of the four groups (Table 3 ). Masson's trichrome staining (data not shown).
3 .4. Myocardial 1,2-DAG and ceramide contents 3 .3. Myocardial lipid content Fig. 2 shows myocardial 1,2-DAG contents of the four Myocardial triglyceride (TG) contents were significantly groups. There were no statistically significant differences increased in both the JVS and etomoxir-treated groups in the amounts of 1,2-DAG between the JVS and control compared with those in the control group. Those in the groups at 4 weeks of age (730675 ng / mg dry weight in carnitine-treated JVS group were decreased compared with control group versus 9756140 ng / mg dry weight in JVS group, NS). However, at 8 weeks of age, the amounts of 3 .5. Fatty acid composition of 1,2-DAG 1,2-DAG were significantly elevated in both the JVS and etomoxir-treated groups (585658 ng / mg dry weight in the We compared the fatty acid composition of 1,2-DAG control versus 1677654 ng / mg dry weight in the JVS between the control and JVS groups at 4 weeks of age group and 12586109 ng / mg dry weight in the etomoxir- (Fig. 3a) ; furthermore, that of 1,2-DAG among the control, treated group; P,0.01) (Fig. 2a) . In the carnitine-treated JVS, carnitine-treated JVS and etomoxir-treated groups JVS group, the mass of 1,2-DAG was decreased compared were compared at 8 weeks of age (Fig. 3b) . There was a with that of the JVS group. No difference in the amounts significant difference in the fatty acid profile of 1,2-DAG of ceramide was observed among the four groups (Fig. 2b) .
between the control and JVS groups, but the fatty acid composition of 1,2-DAG in carnitine-treated JVS mice was other groups. Other fatty acid species of 1,2-DAG resimilar to that in the control, except for 18:1(n29) and mained unchanged. 18:2(n26) fatty acids. Moreover, the profile of the fatty acid composition of 1,2-DAG in the etomoxir-treated 3 .6. Fatty acid composition of phosphatidylcholine, control group was similar to that in the JVS group. In the phosphatidylinositol and triglyceride JVS and control groups, a consistent pattern was observed between 4 and 8 weeks of age. The percentages of 14:0, With respect to the fatty acid composition of 1,2-DAG, 16:0, 22:1 and 22:6(n23) fatty acids were significantly the percentages of 18:1(n29) and 18:2(n26) fatty acids decreased in both the JVS and etomoxir-treated groups;
were significantly increased and those of 16:0 and 22:6(n2 those of 18:1(n29) and 18:2(n26) fatty acids were much 3) fatty acids were significantly decreased in the JVS as higher in both the JVS and etomoxir-treated groups than in compared with the control group. These differences be- tween the JVS and control groups were more similar to 18:1(n29) and 18:2(n26), are important as a signal those in phosphatidylcholine (PC) than those in phospharelated to cardiac hypertrophy. It has been reported that the tidylinositol (PI). In contrast to PC, only a slight difference amounts of 1,2-DAG are elevated in response to a in the fatty acid composition of PI was seen between the stimulating event in vivo and in vitro [15, 16] . We previouscontrol and JVS groups, except for slight increases in ly reported that the amounts of 1,2-DAG are elevated in 18:1(n29) and 18:2(n26) in the JVS group. With respect the hypertrophic heart in the Bio 14.6 hamster [17] . In to the fatty acid composition of TG, the percentage of addition, Milano et al. demonstrated the elevation of 1,2-18:1(n29) was significantly increased, but that of 18:2(n2 DAG in cardiac hypertrophy of overexpressing constitu-6) was no different between the control and JVS groups tively active mutant a -adrenergenic receptor transgenic 1B (Fig. 4) . mice [18] . In vitro, many experiments have demonstrated that the 1,2-DAG level is raised by the stimulation of cultured cells. Also, Eskildsen-Helmond et al. showed that 4 . Discussion the distinct molecular species composition of 1,2-DAG is related to the activation of PKC [19] . The above findings, Mitochondrial b-oxidation of fatty acids is the main taken together, lead us to believe that the increase in, and source of energy for the heart. It is well known that a altered composition of, the total level of 1,2-DAG may disorder of b-oxidation causes cardiac hypertrophy [1] .
play a role in activating the PKC pathway, resulting in the However, the precise mechanisms of cardiac hypertrophy development of cardiac hypertrophy. in such disorders are poorly understood. In this study, we 1,2-DAG is generated through several pathways: de used two models of cardiac hypertrophy resulting from the novo synthesis [20, 21] and hydrolysis of PC [22] [23] [24] , PI disorder of b-oxidation: the JVS mouse, which exhibits [25] [26] [27] or other lipids such as phosphatidylethanolamine hereditary systemic carnitine deficiency, and the etomoxir- [28] . In general, the production of 1,2-DAG shows a treated control mouse, in which fatty acid utilization is biphasic pattern after stimulation [29] . The initial phase of impaired by inhibiting CPT-1. Moreover, a model of increase in 1,2-DAG is predominantly derived from PI, inhibition of cardiac hypertrophy, carnitine-treated JVS whereas the late phase of 1,2-DAG increase is produced mice, was used for comparison with these b-oxidation from PC [30] . DAGs derived from PC, which usually show disorder models. In both of these b-oxidation disorder a more sustained peak than do those from PI, have been models, the concentrations of total lipids in the heart were suggested to lead to a sustained PKC activation [19] . The significantly increased compared with those in the control fatty acid patterns of PC and PI do not change after agonist and carnitine-treated JVS models. Therefore, we consider stimulation, and the DAGs derived from PC can be that the evaluation of lipid second messengers might be distinguished from those derived from PI based on their important for elucidating the pathogenesis of cardiac fatty acid composition profiles [31] . In this study, 1,2-DAG hypertrophy. There have been few reports regarding the in the hypertrophied heart may be derived mainly from PC, level of 1,2-DAG directly measured in the hypertrophied judging from the fatty acid composition of 1,2-DAG. Since heart [15, 16] . In this study, we evaluated myocardial 1,2-cardiac hypertrophy developed gradually in both hereditary DAG and ceramide levels by means of the TLC / FID and drug-induced models, sustained stimuli may be necestechnique.
sary to cause it. Moreover, the fatty acid pattern of TG is To our knowledge, this is the first report to demonstrate not basically coincident with that of 1,2-DAG. Therefore, that the amounts of 1,2-DAG are significantly increased in the elevated 1,2-DAG does not appear to be derived from the hypertrophied heart as a result of energy metabolic TG. Only a few studies have been reported about the disorder. Moreover, distinct fatty acids such as 18:1(n29) function of TG as a signal. and 18:2(n26) were significantly increased in both the Furthermore, the 18:1(n29) and 18:2(n26) fatty acid JVS and etomoxir-treated mice. The fatty acid profile of compositions of PI were increased in the JVS group of 1,2-DAG was similar between the JVS and etomoxircardiac hypertrophy, suggesting that the phosphatidylinotreated groups, whereas in carnitine-treated JVS mice, the sitol 4,5-bisphosphate phospholipase C (PIP -PLC) path-2 amount of 1,2-DAG was significantly decreased and the way may also participate, to some extent, in regulating fatty acid composition of 1,2-DAG was different compared 1,2-DAG production. It is known that 1,2-DAG derived with that in JVS mice. Previous reports have suggested from PIP -PLC activates PKCs ubiquitously. Therefore, 2 that 1,2-DAG, which is considered to be only one of the the possibility cannot be excluded that this increased 1,2-physiological activators of PKC, might exert cardiac DAG may be derived from PI and PC together. At present, hypertrophy by both its increased total level and by the although the accumulated 1,2-DAG under different conaltered composition of particular molecular species [8] .
ditions was characterized differently, previous studies have These results also demonstrate that the amounts of 1,2-not sufficiently revealed whether different 1,2-DAG DAG have been elevated and the fatty acid compositions species are active, or where these lipids are located and of 1,2-DAG have been altered. This suggests that the how they contribute to the specificity. specific molecular species composition of 1,2-DAG, Three potential pathways of PC utilization result in monounsaturated phosphatidic acids (PAs) exhibit activity as signaling molecules [42] rated PA may be changed into monounsaturated DAG. In any event, we believe that not only the increase in the total level of 1,2-DAG, but the altered composition of distinct 1,2-DAG generation: the phosphatidylcholine-phospholipfatty acids, may activate the PKC pathway. ase C (PC-PLC) pathway, the phosphatidylcholine-phos-
In conclusion, changes in the lipid second messenger pholipase D (PC-PLD) followed by phosphatidic acid 1,2-DAG and ceramide in the hypertrophied heart resulting phosphatase (PAP) activation pathway, and the conversion from a b-oxidation disorder are similar between hereditary of ceramide to sphingomyelin catalysed by PC (Fig. 5 ). It and pharmacological interventional models. 1,2-DAG may has been suggested that PC-PLC is unlikely to play a role be involved in the pathogenesis of cardiac hypertrophy in regulating the 1,2-DAG concentration in agonist-stimuresulting from an energy metabolic disorder. lated cells [32, 33] . A few studies have investigated the possibility that 1,2-DAG is generated as a consequence of stimulated sphingomyelin synthesis (SMS). SMS catalyzes A cknowledgements the transfer of the phosphorylcholine group from PC to ceramide, resulting in the formation of sphingomyelin and
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